Improved survival with MEK inhibition in BRAF-mutated melanoma

About 160,000 new cases of melanoma are diagnosed and 48,000 melanoma-related deaths occur worldwide each year.1 Among cancers in patients under 40 years of age, the incidence of melanoma is second only to that of breast cancer for women and leukemia for men.2 Before 2010, no systemic therapy had be...

Full description

Saved in:
Bibliographic Details
Main Authors: Flaherty, Keith T. (Author) , Hassel, Jessica C. (Author) , Utikal, Jochen (Author)
Format: Article (Journal)
Language:English
Published: June 4, 2012
In: The New England journal of medicine
Year: 2012, Volume: 367, Issue: 2, Pages: 107-114
ISSN:1533-4406
DOI:10.1056/NEJMoa1203421
Online Access:Verlag, Volltext: http://dx.doi.org/10.1056/NEJMoa1203421
Get full text
Author Notes:Keith T. Flaherty, M.D., Caroline Robert, M.D., Ph.D., Peter Hersey, M.D., Ph.D., Paul Nathan, M.D., Ph.D., Claus Garbe, M.D., Mohammed Milhem, M.B., Lev V. Demidov, M.D., Jessica C. Hassel, M.D., Piotr Rutkowski,M.D., Peter Mohr, M.D., Reinhard Dummer, M.D., Uwe Trefzer, M.D., James M.G. Larkin, M.D., Jochen Utikal, M.D., Brigitte Dreno, M.D., Marta Nyakas, M.D., Mark R. Middleton, Ph.D., Jürgen C. Becker, M.D., Ph.D., Michelle Casey, Ph.D., Laurie J. Sherman, R.N., Frank S. Wu, M.D., Ph.D., Daniele Ouellet, Ph.D., Anne-Marie Martin, Ph.D., Kiran Patel, Ph.D., and Dirk Schadendorf M.D., for the METRIC Study Group*
Description
Summary:About 160,000 new cases of melanoma are diagnosed and 48,000 melanoma-related deaths occur worldwide each year.1 Among cancers in patients under 40 years of age, the incidence of melanoma is second only to that of breast cancer for women and leukemia for men.2 Before 2010, no systemic therapy had been shown to improve overall survival among patients with metastatic melanoma, and only modest improvements were observed with interferon as an adjuvant drug.3 Ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and vemurafenib, a selective BRAF inhibitor, have both been shown to improve survival among patients with metastatic melanoma . . .
Item Description:Gesehen am 21.08.2019
Physical Description:Online Resource
ISSN:1533-4406
DOI:10.1056/NEJMoa1203421